Screening for Pancreatic Cancer in New-Onset and Deteriorating Diabetes: PANDOME Trial Findings

Overview

The PANDOME trial screened 109 individuals aged ≥50 with new-onset or deteriorating diabetes using MRI-based imaging, detecting one early-stage pancreatic ductal adenocarcinoma (0.9% detection rate). The study highlights the importance of including deteriorating diabetes patients in pancreatic cancer screening and underscores endocrinologists' key role in referrals.

Background

Pancreatic ductal adenocarcinoma (PC) is a highly lethal cancer with poor survival due to late-stage diagnosis. New-onset diabetes (NOD) in individuals aged 50 and older increases PC risk 6- to 8-fold, making this group a prime target for early detection. Deteriorating diabetes (DD), characterized by worsening glycemic control in longstanding diabetes, may also signal underlying PC. Early detection strategies using imaging modalities like MRI are critical to improve survival outcomes.

Data Highlights

Key Findings

• Among 109 screened individuals, 97 had new-onset diabetes and 12 had deteriorating diabetes.
• The DD cohort was older and exhibited significantly higher HbA1c levels, greater weight loss, and increased insulin requirements compared to the NOD cohort.
• Four pancreatic biopsies were performed due to suspicious MRI findings, resulting in detection of one stage 1 pancreatic ductal adenocarcinoma in the DD group.
• The overall pancreatic cancer detection rate was 0.9% in this sporadic diabetes cohort.
• No safety concerns were identified from benign pancreatic abnormalities or incidental findings on MRI.
• Endocrinologists were the primary referral source for patients with deteriorating diabetes, highlighting their critical role in screening pathways.

Clinical Implications

This study supports the inclusion of patients with deteriorating diabetes alongside those with new-onset diabetes in pancreatic cancer screening programs. MRI-based screening is feasible and safe in this population, enabling early detection of pancreatic cancer at a potentially curable stage. Endocrinologists should be engaged actively in identifying and referring high-risk diabetes patients for pancreatic cancer screening.

Conclusion

The PANDOME trial demonstrates that prospective MRI screening in patients with new-onset or deteriorating diabetes can detect early-stage pancreatic cancer in a sporadic cohort. Incorporating deteriorating diabetes into screening criteria and leveraging endocrinology referrals may improve early detection rates and patient outcomes.

References

1. PANDOME Trial Investigators 2024 -- Screening for Pancreatic Cancer in Patients with Newly Diagnosed or Worsening Diabetes